NKTR - Nektar Therapeutics
| Previous Close | 32.61 |
| Open | 32.84 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 800 |
| Day's Range | 32.46 - 33.91 |
| 52 Week Range | 29.22 - 108.23 |
| Volume | 1,502,695 |
| Avg. Volume | 1,872,951 |
| Market Cap | 5.829B |
| Beta (3Y Monthly) | 3.57 |
| PE Ratio (TTM) | 8.86 |
| EPS (TTM) | 3.78 |
| Earnings Date | May 8, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.18 |
- Motley Fool•10 days ago
3 Stocks That Could Double Your Money
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
- Zacks•15 days ago
Stock Market News For Mar 7, 2019
Benchmarks ended in the red on Wednesday after a slew of weak economic reports weighed on the markets.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of NKTR earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Nektar Therapeutics Earnings Call
- PR Newswire•15 days ago
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
SAN FRANCISCO , March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the Cowen and Company ...
- Investing.com•16 days ago
Biotech Companies Slump Midday With FDA Chief Set to Leave
Gottlieb said in a letter addressed to the agency that he is leaving to be with family.
- GlobeNewswire•17 days ago
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Markit•17 days ago
See what the IHS Markit Score report has to say about Nektar Therapeutics.
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold NKTR had net inflows of $7.01 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•18 days ago
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
- GuruFocus.com•20 days ago
Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. Nektar Therapeutics Inc had annual average EBITDA growth of 1.30% over the past ten years. Warning! GuruFocus has detected 3 Warning Signs with NKTR.
- PR Newswire•20 days ago
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
SAN FRANCISCO , March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study ...
- CNBC•21 days ago
Stocks making the biggest moves midday: Gap, Tesla, L Brands & more
Shares of Tesla fell 7.84 percent after the company's underwhelming announcement that it will be launching its standard Model 3. Barclays analyst Brian Johnson even called it the " un-iPhone moment ." The electric car maker also announced store closures and layoffs in an effort to reduce costs, in addition to stating that the company will not turn a profit during its first quarter. Nektar Therapeutics NKTR — The biopharmaceutical fell nearly 6 percent Friday after reporting fourth-quarter earnings.
- Zacks•21 days ago
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
Motley Fool•21 days agoNektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript
NKTR earnings call for the period ending December 31, 2018.
- PR Newswire•21 days ago
Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
SAN FRANCISCO , Feb. 28, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018 . Cash and investments in ...
- ACCESSWIRE•21 days ago
Nektar Therapeutics to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Nektar Therapeutics (NASDAQ: NKTR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at 5:00 ...
- PR Newswire•22 days ago
Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
SAN FRANCISCO , Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), ...
- TheStreet.com•22 days ago
Nektar Therapeutics Expected to Lose 55 Cents a Share
The stock has risen 8.1% since the company last reported earnings on Nov. 7. Quarterly estimates have fallen 1.2 cent a share in the past month. Jim Cramer and the AAP team are watching the pharmaceuticals sector.
- Investopedia•23 days ago
7 Fundamental Plays for a Stock Picker Market
Goldman Sachs argues that equity investors should pay more attention to company-specific fundamentals than macro trends going forward.
- PR Newswire•24 days ago
Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
SAN FRANCISCO , Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, ...
- Zacks•25 days ago
What's in the Cards for Nektar (NKTR) This Earnings Season?
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
- PR Newswire•28 days ago
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018 , on Thursday, February 28, ...
- Simply Wall St.•29 days ago
Is Nektar Therapeutics (NASDAQ:NKTR) A Financially Strong Company?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Small-caps and large-caps are wildly popular among investors; however, mid-capRead More...
- Business Wire•last month
Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nektar Therapeutics. Nektar develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.
- Motley Fool•last month
3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?
- Reuters•last month
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study. Of the 27 patients with urothelial cancer, 19 percent showed complete response after being treated with the combo therapy using Nektar's NKTR-214, according to data, which was presented at the Genitourinary Cancers Symposium in San Francisco. The disease, which can infect any part of the urinary tract including the renal pelvis and the bladder, is the sixth most common type of cancer in the United States, the company said.
